Solid Biosciences (SLDB) Cash & Equivalents (2017 - 2026)

Solid Biosciences has reported Cash & Equivalents for 10 years, with the latest figure at $297.1 million in Q1 2026.

• Quarterly Cash & Equivalents rose 41.05% year-over-year to $297.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $297.1 million (up 41.05% YoY) and the FY2025 annual result came in at $59.9 million, down 25.34% from the prior year.
• Cash & Equivalents improved to $297.1 million in Q1 2026 per SLDB's latest filing, from $59.9 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $297.1 million in Q1 2026 and troughed at $48.8 million in Q3 2022.
• A 5-year average of $111.4 million and a median of $91.6 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents sank 72.93% in 2022, then soared 79.15% in 2025.
• Over 5 years, Cash & Equivalents stood at $155.4 million in 2022, then sank by 52.37% to $74.0 million in 2023, then increased by 8.4% to $80.2 million in 2024, then fell by 25.34% to $59.9 million in 2025, then jumped by 395.99% to $297.1 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $297.1 million, $59.9 million, and $61.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.